Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by eric40on Sep 15, 2020 10:43pm
183 Views
Post# 31565155

RE:RE:H. C. Wainwright 22nd Annual Global Investment Conference

RE:RE:H. C. Wainwright 22nd Annual Global Investment Conference Cut Galbraith salary and they will save 1 million a month. 

What a joke, Thomvest gave him a 12 millions $ a year salary gift for grabbing the company from existing shareholders

That's how it is when they control a company.

Shareholder of Liminal have the right to vote but their vote worth nothing since Thomvest has the majority of shares.

Hopefully, the FDA will give a YES to the BLA resubmission and this will give a boost to the shareprice. 

We should know within 8 days, by september 23, since the FDA has 14 days to reply after the BLA resubmission.

GLTA
<< Previous
Bullboard Posts
Next >>